D.Western Therapeutics Institute ( (JP:4576) ) has issued an update.
D. Western Therapeutics Institute announced the presentation of late Phase II clinical trial results for their drug H-1337 at the ARVO 2025 conference, highlighting its significant intraocular pressure-lowering effects and tolerability for treating open-angle glaucoma and ocular hypertension. This presentation is expected to enhance the company’s international profile and support its licensing activities, although it will not affect the earnings forecast for the fiscal year ending December 2025.
More about D.Western Therapeutics Institute
D. Western Therapeutics Institute, Inc. (DWTI) is a publicly traded company focused on drug discovery and development, primarily targeting inhibitors of protein kinases. Known for its innovative approach, DWTI has developed drugs like Ripasudil for glaucoma and is investigating other compounds such as DW-1002 and DW-5LBT.
Average Trading Volume: 3,342,671
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen4.62B
For an in-depth examination of 4576 stock, go to TipRanks’ Stock Analysis page.